OKYO Pharma (OKYO) News Today

OKYO Pharma Limited Sponsored ADR (NASDAQ: OKYO) is moving higher today after a wave of mostly positive analyst coverage and a company presentation announcement.

• Positive Sentiment: HC Wainwright reiterated a Buy rating on OKYO Pharma and set a $5.00 price target, which is well above the stock’s recent trading range and suggests meaningful upside. Article Title
• Positive Sentiment: The same analyst team published multi-year earnings estimates for OKYO, signaling continued attention on the company’s long-term pipeline and valuation. Article Title
• Positive Sentiment: OKYO Pharma said it will highlight its neuropathic corneal pain program at the Piper Sandler Virtual Ophthalmology Symposium, which could help keep investor focus on its lead clinical opportunity. Article Title
• Neutral Sentiment: HC Wainwright lowered its price target from $7.00 to $5.00, which is still bullish but suggests a more conservative valuation than before. Article Title
• Neutral Sentiment: The recent short-interest decline reported for OKYO may also be supportive, but it is less immediate than the analyst rating and company update. Article Title

Overall, OKYO Pharma appears to be trading up on renewed analyst optimism, a still-bullish target price, and upcoming visibility for its ophthalmology pain program.